Fig. 5.

Combined regimen of tigecycline and trametinib inhibits both oxidative phosphorylation and glycolysis. (a–b) Oxygen consumption rate (OCR) (a) and Extracellular acidification rate (ECAR) (b) with the regimen of tigecycline and trametinib in MHCC97H and PLC/PRF/5 cells. (c–e) Activity of hexokinase (c) and pyruvate kinase (d), and concentration of extracellular lactate (e) in MHCC97H and PLC/PRF/5 cells with the combined treatment of tigecycline and trametinib. (n = 3). Data are mean ± SEM (P values are calculated by two-tailed unpaired t test). 2-DG, 2-Deoxy-d-glucose; FCCP, Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone.